Please login to the form below

Not currently logged in
Email:
Password:

Neurocrine Biosciences

This page shows the latest Neurocrine Biosciences news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

The approval is also good news for Neurocrine Biosciences, from which AbbVie in-licensed the drug in 2010 for $575 million.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics